Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Antibody Structure01:10

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST).

European journal of cancer (Oxford, England : 1990)·2026
Same author

Solvent-based or nab-paclitaxel plus ramucirumab for pretreated gastric cancer with peritoneal dissemination and prespecified biomarker analysis (P-SELECT/WJOG10617G): a randomised phase 2 trial in Japan.

EClinicalMedicine·2026
Same author

Real-world characterization of patients with advanced or metastatic liposarcoma, including dedifferentiated liposarcoma, in Japan in the MASTER KEY project.

Japanese journal of clinical oncology·2026
Same author

Clinical outcomes and genomic alterations in patients with metastatic malignant phyllodes tumors.

Japanese journal of clinical oncology·2025
Same author

Safety and efficacy of conversion therapy for metastatic esophageal cancer: exploratory analysis of JCOG1314.

Esophagus : official journal of the Japan Esophageal Society·2025
Same author

Metastatic urachal carcinoma treated with trifluridine/tipiracil and bevacizumab: a case report.

International cancer conference journal·2025

Related Experiment Video

Updated: May 15, 2026

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

[Development trends for therapeutic antibody].

Eishi Baba1, Hitoshi Kusaba, Shuji Nakano

  • 1Department of Comprehensive Clinical Oncology, Kyushu University Graduate School of Medical Sciences.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|December 25, 2012
PubMed
Summary

Recent therapeutic antibody advancements offer new cancer treatment options. These include improved antibody designs and novel targets, leading to more effective and safer cancer therapies.

More Related Videos

An Open-Source Framework for Mass Calculation of Antibody-Based Therapeutic Molecules
04:24

An Open-Source Framework for Mass Calculation of Antibody-Based Therapeutic Molecules

Published on: June 16, 2023

Activated Cross-linked Agarose for the Rapid Development of Affinity Chromatography Resins - Antibody Capture as a Case Study
07:53

Activated Cross-linked Agarose for the Rapid Development of Affinity Chromatography Resins - Antibody Capture as a Case Study

Published on: August 16, 2019

Related Experiment Videos

Last Updated: May 15, 2026

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

An Open-Source Framework for Mass Calculation of Antibody-Based Therapeutic Molecules
04:24

An Open-Source Framework for Mass Calculation of Antibody-Based Therapeutic Molecules

Published on: June 16, 2023

Activated Cross-linked Agarose for the Rapid Development of Affinity Chromatography Resins - Antibody Capture as a Case Study
07:53

Activated Cross-linked Agarose for the Rapid Development of Affinity Chromatography Resins - Antibody Capture as a Case Study

Published on: August 16, 2019

Area of Science:

  • Immunotherapy
  • Oncology
  • Biotechnology

Context:

  • Therapeutic antibodies are crucial in modern cancer treatment.
  • Existing antibody therapies face challenges in efficacy and safety.
  • Advancements in antibody engineering and target identification are ongoing.

Purpose:

  • To summarize recent developments in therapeutic antibody technology for cancer treatment.
  • To highlight novel antibody constructs and targets enhancing anti-tumor immunity.
  • To discuss the potential for improved cancer therapy outcomes.

Summary:

  • Antibody molecules are being modified to improve Fcgamma receptor binding and cellular recycling.
  • New antibody constructs with multivalent specificity and conjugated agents have been developed.
  • Exploration of novel targets has led to antibodies like anti-CTLA-4, enhancing anti-tumor immunity.

Impact:

  • These advancements promise more effective and safer therapeutic options for various cancers.
  • Improved antibody efficacy and targeted immune responses can lead to better patient outcomes.
  • The evolution of therapeutic antibodies signifies a paradigm shift in oncology treatment strategies.